title: A strategic framework for novel drug development in multiple myeloma.
authors.affiliation: Department of Medicine, Harvard Medical School, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Alison L
authors.initials: AL
authors.lastname: Hannah
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
authors.forename: Ann T
authors.initials: AT
authors.lastname: Farrell
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor